tiprankstipranks
3 Best Stocks to Buy Now, 7/18/2023, According to Top Analysts
Stock Analysis & Ideas

3 Best Stocks to Buy Now, 7/18/2023, According to Top Analysts

Which stocks are best to buy now? According to top Wall Street analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as well.

Don't Miss our Black Friday Offers:

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by top-ranking analysts.

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

Targa Resources (NYSE:TRGP– Targa provides midstream natural gas and natural gas liquids services globally. Today, Barclays analyst Theresa Chen reiterated a Buy rating on the stock with a price target of $89. All eight top analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of nearly 25%.

Ascendis Pharma (NASDAQ:ASND– The biopharmaceutical company focuses on developing drugs for endocrinology and oncology indications. Today, Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on the stock with a price target of $107. The stock has received Buy ratings from all five top analysts who have recently rated it. Collectively, the consensus 12-month price target suggests an increase of nearly 71%. 

Chord Energy (NASDAQ:CHRD) – The company is engaged in hydrocarbon exploration and hydraulic fracturing. Yesterday, RBC Capital analyst Scott Hanold maintained a Buy rating on the stock with a $180 price target. All four top analysts who recently rated the stock gave it a Buy. Collectively, their 12-month price targets imply an upside of nearly 32%.

Who are the Top Analysts?

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. See real-time analyst rankings and learn more about the performance of top analysts on TipRanks’ Top Wall Street Analysts page.

Disclosure

Related Articles
TheFlyAscendis Pharma price target raised to $207 from $200 at Stifel
TheFlyAscendis Pharma price target lowered to $153 from $160 at TD Cowen
TipRanks Auto-Generated NewsdeskAscendis Pharma Reports Strong Q3 2024 Results
Go Ad-Free with Our App